Literature DB >> 15256762

Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese.

Makoto Nagano1, Shizuya Yamashita, Ken-Ichi Hirano, Mayumi Takano, Takao Maruyama, Mitsuaki Ishihara, Yukiko Sagehashi, Takeshi Kujiraoka, Kazuya Tanaka, Hiroaki Hattori, Naohiko Sakai, Norimichi Nakajima, Tohru Egashira, Yuji Matsuzawa.   

Abstract

Plasma cholesteryl ester transfer protein (CETP) facilitates the transfer of cholesteryl ester (CE) from high density lipoprotein (HDL) to apolipoprotein B-containing lipoproteins. Since CETP regulates the plasma levels of HDL cholesterol and the size of HDL particles, CETP is considered to be a key protein in reverse cholesterol transport (RCT), a protective system against atherosclerosis. The importance of plasma CETP in lipoprotein metabolism was demonstrated by the discovery of CETP-deficient subjects with marked hyperalphalipoproteinemia (HALP). Genetic CETP deficiency is the most important and common cause of HALP in the Japanese. Ten mutations of the CETP gene have been demonstrated as causes of HALP, including two common mutations: an intron 14 splicing defect (Int14 + 1 G --> A) and an exon 15 missense mutation (D442G). The subjects with CETP deficiency show a variety of abnormalities in the concentration, composition, and function of both HDL and low density lipoprotein (LDL). CETP deficiency is considered a physiological state of impaired RCT, which may possibly lead to the development of atherosclerosis despite high HDL cholesterol levels. However, the pathophysiological significance of CETP in terms of atherosclerosis has been controversial. Epidemiological studies in Japanese-Americans living in Hawaii and Japanese in the Omagari area, where HALP subjects with an intron 14 splicing defect of the CETP gene are markedly frequent, have shown a relatively increased incidence of coronary atherosclerosis in CETP deficiency. On the other hand, the TaqIB polymorphism-B2 allele with low CETP mass and increased HDL cholesterol has been related to a decreased risk for coronary heart disease (CHD) in many studies, including the Framingham Offspring Study. The current review focused on the characterization of the Japanese subjects with CETP deficiency, including our recent findings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15256762     DOI: 10.5551/jat.11.110

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  31 in total

1.  Biochemical characterization of cholesteryl ester transfer protein inhibitors.

Authors:  Mollie Ranalletta; Kathleen K Bierilo; Ying Chen; Denise Milot; Qing Chen; Elaine Tung; Caroline Houde; Nadine H Elowe; Margarita Garcia-Calvo; Gene Porter; Suzanne Eveland; Betsy Frantz-Wattley; Mike Kavana; George Addona; Peter Sinclair; Carl Sparrow; Edward A O'Neill; Ken S Koblan; Ayesha Sitlani; Brian Hubbard; Timothy S Fisher
Journal:  J Lipid Res       Date:  2010-05-10       Impact factor: 5.922

2.  HDL and CETP Inhibition: Will This DEFINE the Future?

Authors:  Michael H Davidson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

3.  Genetic variants affecting alternative splicing of human cholesteryl ester transfer protein.

Authors:  Adam Suhy; Katherine Hartmann; Leslie Newman; Audrey Papp; Thomas Toneff; Vivian Hook; Wolfgang Sadee
Journal:  Biochem Biophys Res Commun       Date:  2014-01-03       Impact factor: 3.575

4.  Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients.

Authors:  Hamid Moradi; Elani Streja; Moti L Kashyap; Nosratola D Vaziri; Gregg C Fonarow; Kamyar Kalantar-Zadeh
Journal:  Nephrol Dial Transplant       Date:  2014-02-25       Impact factor: 5.992

Review 5.  Human genetics of variation in high-density lipoprotein cholesterol.

Authors:  Atif Qasim; Daniel J Rader
Journal:  Curr Atheroscler Rep       Date:  2006-05       Impact factor: 5.113

Review 6.  High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome.

Authors:  R A Wilke
Journal:  Pharmacogenomics J       Date:  2010-12-14       Impact factor: 3.550

Review 7.  Familial dyslipidaemias: an overview of genetics, pathophysiology and management.

Authors:  Sahar B Hachem; Arshag D Mooradian
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 8.  Cholesteryl ester transfer protein and its inhibition.

Authors:  Olaf Weber; Hilmar Bischoff; Carsten Schmeck; Michael-Friedrich Böttcher
Journal:  Cell Mol Life Sci       Date:  2010-06-18       Impact factor: 9.261

9.  Cholesteryl ester transfer protein gene polymorphisms and longevity syndrome.

Authors:  Genovefa Kolovou; Marianna Stamatelatou; Katherine Anagnostopoulou; Peggy Kostakou; Vana Kolovou; Constantinos Mihas; Ioannis Vasiliadis; Olga Diakoumakou; Dimitri P Mikhailidis; Dennis V Cokkinos
Journal:  Open Cardiovasc Med J       Date:  2010-01-29

10.  Cholesteryl ester transfer protein genetic polymorphisms, HDL cholesterol, and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis.

Authors:  Michael Y Tsai; Craig Johnson; W H Linda Kao; A Richey Sharrett; Valerie L Arends; Richard Kronmal; Nancy Swords Jenny; David R Jacobs; Donna Arnett; Daniel O'Leary; Wendy Post
Journal:  Atherosclerosis       Date:  2008-02-20       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.